HUGEL announced on the 8th that its consolidated operating profit for the first quarter of this year was 39 billion won, marking a 62.6% increase compared to the same period last year. During the same period, sales amounted to 89.8 billion won, up 20.9% year-on-year, achieving the highest first-quarter performance in history.
The company attributed this performance to balanced growth across all product categories. First, sales of the botulinum toxin product "Botulax" amounted to 40.7 billion won, accounting for 45% of total sales. By region, the Asia-Pacific (including China, Australia, and Taiwan) showed the highest growth, increasing by 54% compared to the same period last year.
Hyaluronic acid (HA) fillers ("The Chaeum," "VYRIDEN Skin Booster HA") also achieved sales of 34.4 billion won, an increase of 17.7% compared to the same period last year. Strong sales were evident not only in the domestic market but also across the Asia-Pacific, North America, and Europe.
The cosmetics ("Wellage," "VYRIDEN BR") sector also recorded sales of 13.2 billion won, an increase of 39.3% compared to the same period last year. The derma cosmetic brand "Wellage" and the high-end cosmetic brand "VYRIDEN BR" are continuing to expand points of consumer contact through consecutive new product launches and diversification of distribution channels both domestically and internationally.
A HUGEL official noted, "Through company-wide efforts, all of HUGEL's product lines are consistently excelling in both domestic and international markets, achieving another encouraging result of the largest first-quarter performance on record," adding, "We will strive to solidify our presence in the global market, leveraging upcoming U.S. shipments and entry into the Middle East as momentum."